Search Blog
Categories
May 2018
M T W T F S S
« Apr   Jun »
 123456
78910111213
14151617181920
21222324252627
28293031  

Tags

Deadline Alert for Solid Biosciences, Inc. Shareholders in Class Action Lawsuit – SLDB

ACCESSWIRE

By Kaskela Law LLC

RADNOR, PA / ACCESSWIRE / May 8, 2018 / Kaskela Law LLC alerts Solid Biosciences, Inc. (NASDAQ: SLDB) (“Solid Biosciences” or the “Company”) investors that a class action lawsuit has been filed on behalf of purchasers of the Company’s securities between January 25, 2018 and March 14, 2018, inclusive (the “Class Period”).

DEADLINE ALERT: Investors who purchased Solid Biosciences securities during the Class Period may, no later than May 28, 2018, seek to be appointed as a lead plaintiff representative of the investor class. Solid Biosciences investors are encouraged to visit www.kaskelalaw.com/case/solid-biosciences-inc/ to receive additional information about this action and submit their information online.

On or around January 25, 2018, Solid Biosciences completed an initial public offering (“IPO”) of its common stock, selling 7,000,000 shares of stock to investors at $16.00 per share.

The shareholder class action complaint alleges that Solid Biosciences and certain of its executive officers made a series of false and misleading statements and/or failed to disclose to investors that: (i) Solid Biosciences’ lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; and (ii) Solid Biosciences had misled investors regarding the toxicity of SGT-001. The complaint further alleges that, as a result of the foregoing, investors purchased Solid Biosciences’ common stock at artificially inflated prices during the Class Period and sustained significant investment losses when the truth was revealed.

On March 14, 2018, Solid Biosciences disclosed that the U.S. Food and Drug Administration had placed a clinical hold on its SGT-001 Phase I/II clinical trial, IGNITE DMD. Following this news, shares of Solid Biosciences’ common stock fell $16.99 per share, or over 60%, to close on March 15, 2018 at $9.32.

Kaskela Law LLC exclusively prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
201 King of Prussia Road
Suite 650
Radnor, PA 19087
(888)-715-1740
skaskela@kaskelalaw.com
www.kaskelalaw.com

SOURCE: Kaskela Law LLC

ReleaseID: 499010